Avadel Pharmaceuticals (AVDL)
(Real Time Quote from BATS)
$12.66 USD
-0.21 (-1.63%)
Updated Sep 24, 2024 11:20 AM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
AVDL 12.66 -0.21(-1.63%)
Will AVDL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVDL
Are Medical Stocks Lagging DaVita (DVA) This Year?
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Other News for AVDL
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary
Avadel Pharmaceuticals PLC (AVDL) Trading Down 3.73% on Sep 23
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Avadel Pharmaceuticals call volume above normal and directionally bullish
Avadel Pharmaceuticals call volume above normal and directionally bullish